Escape from senescence: revisiting cancer therapeutic strategies

Although senescence has been considered as an irreversible cell arrest state, accumulating evidence challenge this view. Consequently, senescence appears as an imperfect barrier to impede cancer progression, constituting a step prior to disease relapse. Therefore, cancer treatment strategies may ben...

Descripción completa

Detalles Bibliográficos
Autores principales: Zampetidis, Christos P., Papantonis, Argyris, Gorgoulis, Vassilis G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2022
Materias:
Author’s View
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8890391/
https://www.ncbi.nlm.nih.gov/pubmed/35252554
http://dx.doi.org/10.1080/23723556.2022.2030158
_version_ 1784661626409975808
author Zampetidis, Christos P.
Papantonis, Argyris
Gorgoulis, Vassilis G.
author_facet Zampetidis, Christos P.
Papantonis, Argyris
Gorgoulis, Vassilis G.
author_sort Zampetidis, Christos P.
collection PubMed
description Although senescence has been considered as an irreversible cell arrest state, accumulating evidence challenge this view. Consequently, senescence appears as an imperfect barrier to impede cancer progression, constituting a step prior to disease relapse. Therefore, cancer treatment strategies may benefit if revisited to include senolytic agents.
format Online
Article
Text
id pubmed-8890391
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Taylor & Francis
record_format MEDLINE/PubMed
spelling pubmed-88903912022-03-03 Escape from senescence: revisiting cancer therapeutic strategies Zampetidis, Christos P. Papantonis, Argyris Gorgoulis, Vassilis G. Mol Cell Oncol Author’s View Although senescence has been considered as an irreversible cell arrest state, accumulating evidence challenge this view. Consequently, senescence appears as an imperfect barrier to impede cancer progression, constituting a step prior to disease relapse. Therefore, cancer treatment strategies may benefit if revisited to include senolytic agents. Taylor & Francis 2022-02-15 /pmc/articles/PMC8890391/ /pubmed/35252554 http://dx.doi.org/10.1080/23723556.2022.2030158 Text en © 2022 The Author(s). Published with license by Taylor & Francis Group, LLC. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Author’s View
Zampetidis, Christos P.
Papantonis, Argyris
Gorgoulis, Vassilis G.
Escape from senescence: revisiting cancer therapeutic strategies
title Escape from senescence: revisiting cancer therapeutic strategies
title_full Escape from senescence: revisiting cancer therapeutic strategies
title_fullStr Escape from senescence: revisiting cancer therapeutic strategies
title_full_unstemmed Escape from senescence: revisiting cancer therapeutic strategies
title_short Escape from senescence: revisiting cancer therapeutic strategies
title_sort escape from senescence: revisiting cancer therapeutic strategies
topic Author’s View
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8890391/
https://www.ncbi.nlm.nih.gov/pubmed/35252554
http://dx.doi.org/10.1080/23723556.2022.2030158
work_keys_str_mv AT zampetidischristosp escapefromsenescencerevisitingcancertherapeuticstrategies
AT papantonisargyris escapefromsenescencerevisitingcancertherapeuticstrategies
AT gorgoulisvassilisg escapefromsenescencerevisitingcancertherapeuticstrategies

Ejemplares similares